Cerus Corp (NASDAQ:CERS)

CAPS Rating: 2 out of 5

The Company develops and commercializes novel, proprietary products and technologies within the fields of blood safety and immunotherapy that provides safer and more medical options to patients in areas of unmet medical need.

Results 1 - 18 of 18

Recs

0
Member Avatar Saveupnow (< 20) Submitted: 2/13/2014 2:25:47 PM : Outperform Start Price: $7.29 CERS Score: -53.29

FDA approval expected this year, need cleaner blood and plasma

Recs

0
Member Avatar IFindKaching (< 20) Submitted: 4/18/2011 12:38:26 PM : Outperform Start Price: $2.73 CERS Score: +0.72

CERS is the best option in the critical market for blood supply protection. Already accepted in Europe and other parts of the world, it's only a matter of time for FDA approval in the US. When that happens...

Recs

0
Member Avatar EclecticRecluse (80.20) Submitted: 3/18/2011 3:58:46 AM : Underperform Start Price: $2.51 CERS Score: -13.74

Weakening Earnings Opinion

Recs

0
Member Avatar fafpgcnl (< 20) Submitted: 1/10/2011 5:44:27 PM : Outperform Start Price: $2.82 CERS Score: -7.26

There is significant risk here due to there low cash and the need for FDA approval for their blood treatment. However, if things go well the upside is huge.

Recs

1
Member Avatar flstfi88 (23.67) Submitted: 4/26/2010 7:20:57 AM : Outperform Start Price: $3.35 CERS Score: -39.36

The Intercept system will be approved by the FDA for the US and this will become very profitable.

Recs

0
Member Avatar utosweet (23.18) Submitted: 2/4/2008 10:52:15 AM : Outperform Start Price: $6.39 CERS Score: -87.41

Looking to enter the US market sometime soon ? Blood enhansement looks very good.

Recs

0
Member Avatar FundamentalGamma (40.72) Submitted: 12/8/2007 9:31:11 PM : Underperform Start Price: $6.96 CERS Score: +80.72

FS = 26
Gamma = .41

Fundamentals bad, price very overvalued.

Recs

0
Member Avatar tarst33 (23.26) Submitted: 7/31/2007 11:00:12 AM : Outperform Start Price: $6.29 CERS Score: -78.00

Will be in the US market in 1-2 years.

Recs

0
Member Avatar mooman1963 (30.53) Submitted: 6/7/2007 10:12:02 PM : Outperform Start Price: $6.07 CERS Score: -74.51

Patented blood cleansing technology is state of the art. Look for this company to be in every major hospital and blood bank within 5 years

Recs

0
Member Avatar murleygraves (23.73) Submitted: 4/23/2007 6:36:34 AM : Outperform Start Price: $7.63 CERS Score: -90.42

Insider buying

Recs

0
Member Avatar wtfn69 (75.63) Submitted: 4/18/2007 12:23:40 PM : Outperform Start Price: $7.59 CERS Score: -91.33

US earnings coming around 08. A much needed fix in the healthcare world

Recs

0
Member Avatar skiblaise1 (< 20) Submitted: 3/10/2007 10:45:20 AM : Outperform Start Price: $6.43 CERS Score: -88.68

european dominno effect on revenues with maintained costs. Outstanding intl. sales mgt return to equity.

Recs

0
Member Avatar fullwealth (< 20) Submitted: 3/9/2007 12:30:12 PM : Outperform Start Price: $6.33 CERS Score: -86.95

Excellent blood product Intercept growing sales in international markets

Recs

0
Member Avatar AJL203PSU (< 20) Submitted: 3/7/2007 12:22:32 AM : Outperform Start Price: $5.72 CERS Score: -81.13

I&quot;m not really a biotech investor. I really don't know how to value them. With that said I like what CERUS is doing and like their approach to cleaning a vital link in healthcares chain.

Recs

0
Member Avatar ldnelson (36.50) Submitted: 1/20/2007 9:34:02 AM : Outperform Start Price: $5.80 CERS Score: -78.36

Sleeper with a break thru process

Recs

0
Member Avatar stockuptoday (< 20) Submitted: 12/29/2006 1:48:38 PM : Outperform Start Price: $5.96 CERS Score: -81.57

Cerus Corp. has received a $5 million milestone payment from BioOne Corp., the company said Tuesday.

Cerus (NASDAQ: CERS), which is located in Concord, received the payment after its Intercept Blood System for plasma was approved by European regulators.Early next year, Tokyo-based BioOne will make another milestone payment of $5 million in stock.

The two companies inked a deal over the Intercept device in June 2005. BioOne holds the rights to sell the device in parts of Asia.

Recs

0
Member Avatar drkennyg (< 20) Submitted: 10/12/2006 7:42:14 PM : Outperform Start Price: $6.61 CERS Score: -95.48

great blood products with increasing demand on the horizon

Recs

4
Member Avatar mansloth (98.84) Submitted: 8/22/2006 9:02:15 PM : Outperform Start Price: $5.40 CERS Score: -88.70

This is probably the riskiest pick in my CAPS portfolio, and I would strongly caution against picking this for yourself.

I'm picking this becauase I believe thier strategy with CRS-100 is likely to go all the way. Their blood safety system should provide modest revenues in the short term, but I'm banking that they will get a partner for CRS-100 in the next 2-4 years and eventually develop more Listeria-based therapies.

Results 1 - 18 of 18

Featured Broker Partners


Advertisement